文献速递垂体与肾上腺疾病

库欣病术后复发风险与USP8基因型及肿瘤大小的关联:国际回顾性纵向队列研究

Risk of recurrence after successful surgery for Cushing's disease and association with USP8 genotype and tumour size: an international, retrospective, longitudinal cohort study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2026-03-02

该国际回顾性纵向队列研究纳入435例库欣病患者,分析USP8状态与术后复发的关系。USP8突变型和大腺瘤野生型患者复发风险显著高于微腺瘤野生型,联合基因型与肿瘤大小可优化风险分层。

要点

  • USP8突变型与大腺瘤野生型复发风险均显著高于微腺瘤野生型。

核心结论

  • USP8基因型联合肿瘤大小可识别库欣病术后复发高风险患者,尤其在大异质性非侵袭性肿瘤或术后皮质醇偏低的标准评估非高危组中。

研究设计与样本

  • 国际回顾性纵向队列研究,纳入东亚、欧洲和北美8家三级中心1989年1月1日至2024年4月1日首次垂体手术的库欣病患者435例,女360例(83%),男75例(17%)。

主要发现

  • 195例(45%)检测到USP8变异。
  • 371例即刻缓解患者中66例(18%)记录复发。

关键数值与推荐

  • USP8突变型微腺瘤与大腺瘤累积复发风险相似,合并为单一风险组。
  • 复发风险比较以野生型微腺瘤为参照,校正年龄、术后最低血清皮质醇、肿瘤侵袭和种族或中心。

临床怎么用

  • 对库欣病术后患者联合检测USP8状态与肿瘤大小,可更准确评估复发风险。
  • 对USP8突变型肿瘤或野生型大腺瘤患者,即使非侵袭性或术后皮质醇偏低,也应考虑更密切长期随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recurrence after successful pituitary surgery remains a challenge in the management of patients with Cushing's disease, with no reliable predictors of long-term outcome. Pathogenic somatic USP8 variants are found in one third of cases and their association with recurrence is unclear. The aim of this study was to determine the association between USP8 status and postoperative outcome. METHODS: This international, retrospective, longitudinal study was done in eight tertiary centres in east Asia, Europe, and North America. We reviewed clinical records and genetic information of patients with clinically diagnosed and pathologically confirmed Cushing's disease who underwent first pituitary surgery in any of the participating centres between Jan 1, 1989, and April 1, 2024. Inclusion criteria were postoperative follow-up of at least 3 months after first pituitary surgery, known postsurgical outcome, and tissue availability or known USP8 status. The primary outcomes were recurrence and time to recurrence after first surgery. We assessed recurrence-free intervals and recurrence risk using survival analysis, multivariate logistic regression, and Cox proportional hazards models. FINDINGS: We retrospectively retrieved and examined clinical records from 558 patients, 123 of whom were excluded. 360 (83%) of 435 patients were female and 75 (17%) were male. We detected USP8 variants in 195 (45%) cases. Recurrence was recorded in 66 (18%) of 371 patients in immediate remission. Risk of recurrence depended on USP8 status and tumour size. Patients with USP8-variant microadenomas and USP8-variant macroadenomas had similar cumulative hazards for recurrence, so they were considered as a single risk group. 10-year recurrence rate was higher for USP8-variant tumours (36·8%, 95% CI 23·7-47·7) than for wildtype microadenomas (15·0%, 4·9-24·0; adjusted p=0·016) but was lower than for wildtype macroadenomas (44·5%, 26·2-58·2; adjusted p=0·025). Patients with USP8-variant tumours (hazard ratio 2·41, 95% CI 1·19-4·87; p=0·014) or wildtype macroadenomas (4·48, 2·11-9·52; p<0·0001) had significantly higher risk of recurrence than patients with wildtype microadenomas, even after adjusting for age, postoperative nadir serum cortisol, tumour invasion, and ethnicity or centre. INTERPRETATION: Combined USP8 genotype-tumour size identified patients at increased risk of recurrence, particularly in largely heterogeneous groups of patients with non-invasive tumours or low postoperative serum cortisol not considered high risk in standard care. Implementing this combined genetic-clinical stratification could provide more accurate risk assessment, indicate those at higher risk of recurrence, and ultimately personalise long-term follow-up in patients with Cushing's disease. FUNDING: Deutsche Forschungsgemeinschaft, National Natural Science Funds of China, and CAMS Innovation Fund for Medical Sciences.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Zhang Q, Cai Y, Liu Y, et al. Risk of recurrence after successful surgery for Cushing's disease and association with USP8 genotype and tumour size: an international, retrospective, longitudinal cohort study. Lancet Diabetes Endocrinol. 2026. PMID: 41785910. doi:10.1016/S2213-8587(25)00396-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。